库库比他素I通过KAT2a-ube2C/E2F1通路诱导细胞循环停止,并抑制HepG2诱导的巨细胞M2极化,从而发挥其抗癌作用
Xiaocheng Gong1, Yunfei Liu1, Keying Liang1
1School of Biology and Biological Engineering, South China University of Technology, Guangzhou, PR China.
Biochemical and biophysical research communications
|August 16, 2024
概括
库库比他素I有效地通过抑制癌细胞生长和促进亡来对抗肝细胞癌 (HCC). 这种天然化合物还调节瘤微环境,为新的HCC疗法显示出希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肝细胞癌 (HCC) 是一个重大的全球健康挑战,特别是在中国,有效的治疗方法有限.
- 由于HCC的高发病率和死亡率,对新型治疗剂的研究至关重要.
研究的目的:
- 系统地评估库库比他素I对肝细胞癌 (HCC) 细胞系的抗癌作用.
- 阐明库库比他素I对HCC的作用背后的分子机制,包括其对亡,细胞循环和瘤微环境的影响.
主要方法:
- 治疗HCC细胞系 (SK-Hep-1,Huh-7,HepG2) 用库库比他素I.
- 细胞增殖,迁移,殖民地形成和细胞亡的评估.
- 对关键的亡相关蛋白质 (Bcl2,P53,Bax,Cas3) 和细胞周期调节剂 (KAT2A,E2F1,UBE2C) 的分析.
- 评估库库比他素I对M2巨细胞两极分化的影响.
主要成果:
- 库库比他素I显著抑制了HCC细胞的增殖,迁移和殖民地形成.
- 该化合物通过改变Bcl2,P53,Bax和Cas3.3的表达来诱导亡.
- 库库比他素I通过KAT2A-E2F1/UBE2C信号通路导致细胞循环停止.
- 库库比他素I抑制了由HCC细胞诱导的巨细胞的M2极化.
结论:
- 库库比塔辛I表现出对HCC的多方面的抗癌特性.
- 这些发现支持库库比塔辛I作为HCC治疗的潜在治疗候选者.
- 对cucurbitacin I的进一步研究可能会导致新的HCC治疗策略.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K


